Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SH009 in Advanced Solid Tumors
NCT07390838Phase 1Recruiting
- Sponsor
- Nanjing Sanhome Pharmaceutical Co., Ltd.
- Start
- May 2025
- Primary completion
- Dec 2026
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SH009 in Solid tumor malignancy, liver cancer, non-small cell lung cancer (NSCLC) and 4 more, sponsored by Nanjing Sanhome Pharmaceutical Co., Ltd. Primary endpoints: Objective Response Rate at 2 years, Duration of Response at 2 years and 4 more. Started May 2025; status: recruiting.
02
Drugs
SH009
03
Conditions
Solid tumor malignancyliver cancernon-small cell lung cancer (NSCLC)head and neck squamous cell carcinoma (HNSCC)breast cancer
Beyond the preview
Go deeper on NCT07390838.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07390838.